𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Brain metastasis in pediatric extracranial solid tumors: survey and literature review

✍ Scribed by Rejin Kebudi; İnci Ayan; Ömer Görgün; Fulya Yaman Ağaoğlu; Sema Vural; Emin Darendeliler


Publisher
Springer US
Year
2005
Tongue
English
Weight
138 KB
Volume
71
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Brain atrophy in children undergoing sys
✍ Prassopoulos, P.; Cavouras, D.; Evlogias, N.; Golfinopoulos, S. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 505 KB

It has been shown that intrathecal chemother-Measurements were compared with corresapy may cause brain damage, which can be ponding normative data. About half of the childepicted in neuroimaging studies. The aim of dren undergoing chemotherapy and half of the this work was to examine possible morpho

Epidural metastasis in Wilms' tumor: A c
✍ Darendeliler, Emin ;Ayan, Inci ;Kebudi, Rejin ;A??ao??lu, Leyla ;Bilge, Nijad ;K 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 496 KB

## Abstract Spinal canal involvement is not a common pattern of metastasis in Wilms' tumor. Although early detection and treatment can achieve improvement of neurological deficit, mortality remains high. We present a 5‐year‐old girl who had an epidural metastasis while she was receiving chemotherap

Subglottic nerve sheath tumor in a pedia
✍ Ronald S. Pulli; John U. Coniglio 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 2 views

## Background: Although nerve sheath tumors (neurilemmoma and neurofibroma) can occur on any nerve with schwann cells, laryngeal involvement is very uncommon. the vast majority of reported laryngeal nerve sheath tumors have been located in the supraglottic area. our case report involves the diagnos

Aziridinylbenzoquinone (AZQ) in the trea
✍ R. P. Castleberry; A. H. Ragab; C. P. Steuber; B. Kamen; S. Toledano; K. Starlin 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 445 KB

To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given ov